Purpose: MAPK and PI3K/AKT/mTOR pathways play important roles in many tumors. In this study, safety, antitumor activity, and pharmacokinetics of buparlisib (pan class PI3K inhibitor) and trametinib (MEK inhibitor) were evaluated.
Experimental Design: This open-label, dose-finding, phase Ib study comprised dose escalation, followed by expansion part in patients with RAS- or BRAF-mutant non-small cell lung, ovarian, or pancreatic cancer.
Results: Of note, 113 patients were enrolled, 66 and 47 in dose-escalation and -expansion parts, respectively. MTD was established as buparlisib 70 mg + trametinib 1.5 mg daily [5/15, 33% patients with dose-limiting toxicities (DLT)] and recommended phase II dose (RP2D) buparlisib 60 mg + trametinib 1.5 mg daily (1/10, 10% patients with DLTs). DLTs included stomatitis (8/103, 8%), diarrhea, dysphagia, and creatine kinase (CK) increase (2/103, 2% each). Treatment-related grade 3/4 adverse events (AEs) occurred in 73 patients (65%); mainly CK increase, stomatitis, AST/ALT (aspartate aminotransferase/alanine aminotransferase) increase, and rash. For all (21) patients with ovarian cancer, overall response rate was 29% [1 complete response, 5 partial responses (PR)], disease control rate 76%, and median progression-free survival was 7 months. Minimal activity was observed in patients with non-small cell lung cancer (1/17 PR) and pancreatic cancer (best overall response was SD). Relative to historical data, buparlisib exposure increased and trametinib exposure slightly increased with the combination.
Conclusions: At RP2D, buparlisib 60 mg + trametinib 1.5 mg daily shows promising antitumor activity for patients with KRAS-mutant ovarian cancer. Long-term tolerability of the combination at RP2D is challenging, due to frequent dose interruptions and reductions for toxicity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1158/1078-0432.CCR-14-1814 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Early Reduction of Glucose Consumption Is a Biomarker of Kinase Inhibitor Efficacy Which Can Be Reversed with GLUT1 Overexpression in Lung Cancer Cells.
Mol Imaging Biol
June 2023
Crump Institute for Molecular Imaging, University of California, Los Angeles, Box 951770, Los Angeles, CA, 90095-1770, USA.
Article Synopsis
- Small molecule inhibitors targeting kinases are crucial for treating non-small cell lung cancer (NSCLC), but they have limitations like varying patient responses, side effects, and lack of reliable biomarkers for efficacy.
- Early changes in tumor glucose consumption, tracked with [F]FDG PET imaging, may predict how well these inhibitors work, but this area is still not fully understood.
- The study shows that effective targeted kinase inhibitors consistently reduce glucose consumption early on, which is important for inhibiting cancer cell growth in NSCLC models.
Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines.
Cancers (Basel)
September 2022
Department of Medicine Clinic III, Hematology, Oncology and Palliative Medicine, Rostock University Medical Center, 18057 Rostock, Germany.
Kirsten rat sarcoma virus () mutations are widespread in pancreatic ductal adenocarcinoma (PDAC) and contribute significantly to tumor initiation, progression, tumor relapse/resistance, and prognosis of patients. Although inhibitors against mutations have been developed, this therapeutic approach is not routinely used in PDAC patients. We investigated the anti-tumor efficacy of two KRAS inhibitors BI-3406 (KRAS::SOS1 inhibitor) and sotorasib (KRAS G12C inhibitor) alone or in combination with MEK1/2 inhibitor trametinib and/or PI3K inhibitor buparlisib in seven PDAC cell lines.
View Article and Find Full Text PDFMolecular landscape of osimertinib resistance in patients and patient-derived preclinical models.
Ther Adv Med Oncol
February 2022
Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, 03722, Republic of KoreaYonsei Cancer Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
Article Synopsis
- Osimertinib, a third-generation EGFR tyrosine kinase inhibitor, is effective for treating patients with -mutant non-small cell lung cancer (NSCLC), but resistance mechanisms were investigated in this study.
- A total of 149 samples were analyzed from 55 NSCLC patients, revealing the most common resistance mutation as C797S (14%), along with various other mutations.
- The study identified potentially targetable mutations and suggested that combination therapies could help overcome resistance, indicating a need for personalized treatment strategies.
Tyrosine Kinase Inhibitors Stimulate HLA Class I Expression by Augmenting the IFNγ/STAT1 Signaling in Hepatocellular Carcinoma Cells.
Front Oncol
August 2021
Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Article Synopsis
- Combination treatments using tyrosine kinase inhibitors (TKIs) and immunotherapies have been effective in managing various cancers, but their impact on HLA-I expression in hepatocellular carcinoma (HCC) is still unclear.
- Regorafenib was found to enhance HLA-I and β2-microglobulin expression in HCC cell lines, influenced by interferon γ (IFNγ) and activated the STAT1 signaling pathway, which is critical for antitumor immunity.
- Other TKIs like sorafenib, lenvatinib, and cabozantinib showed similar effects, with regorafenib being the most effective due to its strong inhibition of the MEK/ERK pathway, suggesting a
Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors.
Int J Mol Sci
August 2019
Kristian Gerhard Jebsen Brain Tumour Research Centre, Department of Biomedicine, University of Bergen, Jonas Lies vei 91, 5009 Bergen, Norway.
Malignant melanoma is the most aggressive type of skin cancer and is closely associated with the development of brain metastases. Despite aggressive treatment, the prognosis has traditionally been poor, necessitating improved therapies. In melanoma, the mitogen activated protein kinase and the phosphoinositide 3-kinase signaling pathways are commonly altered, and therapeutically inhibiting one of the pathways often upregulates the other, leading to resistance.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!